Abstract：
UNASSIGNED: Treatment of contaminated wounds represents a significant challenge in healthcare and there is a need to develop approaches maximising skin retention to maintain therapeutic concentrations of anti-infectives at the wound site. The objective of the present study was to develop and evaluate mupirocin calcium nanolipid emulgels to enhance wound healing performance and patient acceptability.
UNASSIGNED: Nanostructured lipid carriers (NLCs) of mupirocin calcium were prepared by the phase inversion temperature method using Precirol ATO 5 (Gattefosse, India) and oleic acid as lipids and Kolliphor RH 40 (BASF, India) as surfactant and further incorporated into a gel base for topical delivery.
UNASSIGNED: The particle size, polydispersity index and zeta potential of mupirocin NLCs were found to be 128.8±1.25nm, 0.283±0.003 and -24.2±0.56mV, respectively. In vitro release studies from developed emulgel showed sustained drug release over 24 hours. Ex vivo drug permeation studies through excised rat abdominal skin showed better skin permeation (1712.38±15. 57μg/cm2) from developed emulgel compared to marketed ointment (827.92±21.42μg/cm2) after 8 hours, which was in agreement with in vitro antibacterial activity. Studies on Wistar rats indicated the nonirritant potential of developed emulgels. Further, mupirocin emulgels showed improved efficacy in percent wound contraction of acute contaminated open wounds in Wistar rats using a full-thickness excision wound healing model.
UNASSIGNED: The emulgels of mupirocin calcium NLCs appear to be effective in the treatment of contaminated wounds due to increased skin deposition and sustained release, thereby enhancing the wound healing potential of existing molecules.
UNASSIGNED: Nanostructured lipid carriers (NLCs) of mupirocin calcium were prepared by the phase inversion temperature method using Precirol ATO 5 (Gattefosse, India) and oleic acid as lipids and Kolliphor RH 40 (BASF, India) as surfactant and further incorporated into a gel base for topical delivery.
UNASSIGNED: The particle size, polydispersity index and zeta potential of mupirocin NLCs were found to be 128.8±1.25nm, 0.283±0.003 and -24.2±0.56mV, respectively. In vitro release studies from developed emulgel showed sustained drug release over 24 hours. Ex vivo drug permeation studies through excised rat abdominal skin showed better skin permeation (1712.38±15. 57μg/cm2) from developed emulgel compared to marketed ointment (827.92±21.42μg/cm2) after 8 hours, which was in agreement with in vitro antibacterial activity. Studies on Wistar rats indicated the nonirritant potential of developed emulgels. Further, mupirocin emulgels showed improved efficacy in percent wound contraction of acute contaminated open wounds in Wistar rats using a full-thickness excision wound healing model.
UNASSIGNED: The emulgels of mupirocin calcium NLCs appear to be effective in the treatment of contaminated wounds due to increased skin deposition and sustained release, thereby enhancing the wound healing potential of existing molecules.
摘要：
受污染的伤口的治疗代表了医疗保健中的重大挑战,并且需要开发最大化皮肤保留以在伤口部位维持抗感染剂的治疗浓度的方法。本研究的目的是开发和评估莫匹罗星钙纳米脂质乳液，以增强伤口愈合性能和患者可接受性。
■莫匹罗星钙的纳米结构脂质载体（NLCs）是通过使用PrecirolATO5（Gattefosse，印度)和油酸作为脂质和KolliphorRH40(巴斯夫，印度）作为表面活性剂，并进一步掺入凝胶基质中用于局部递送。
■颗粒大小，莫匹罗星NLC的多分散指数和ζ电位为128.8±1.25nm，0.283±0.003和-24.2±0.56mV，分别。来自开发的乳化凝胶的体外释放研究显示药物持续释放超过24小时。通过切除的大鼠腹部皮肤的离体药物渗透研究显示出更好的皮肤渗透(1712.38±15。57μg/cm2）来自开发的乳化剂，8小时后与市售软膏（827.92±21.42μg/cm2）相比，与体外抗菌活性一致。对Wistar大鼠的研究表明，开发的乳液具有无刺激性。Further,使用全层切除伤口愈合模型，莫匹罗星乳液对Wistar大鼠急性污染的开放性伤口的伤口收缩百分比显示出改善的功效。
■由于皮肤沉积增加和持续释放，莫匹罗星钙NLCs的乳液似乎可有效治疗受污染的伤口，从而增强现有分子的伤口愈合潜力。
■莫匹罗星钙的纳米结构脂质载体（NLCs）是通过使用PrecirolATO5（Gattefosse，印度)和油酸作为脂质和KolliphorRH40(巴斯夫，印度）作为表面活性剂，并进一步掺入凝胶基质中用于局部递送。
■颗粒大小，莫匹罗星NLC的多分散指数和ζ电位为128.8±1.25nm，0.283±0.003和-24.2±0.56mV，分别。来自开发的乳化凝胶的体外释放研究显示药物持续释放超过24小时。通过切除的大鼠腹部皮肤的离体药物渗透研究显示出更好的皮肤渗透(1712.38±15。57μg/cm2）来自开发的乳化剂，8小时后与市售软膏（827.92±21.42μg/cm2）相比，与体外抗菌活性一致。对Wistar大鼠的研究表明，开发的乳液具有无刺激性。Further,使用全层切除伤口愈合模型，莫匹罗星乳液对Wistar大鼠急性污染的开放性伤口的伤口收缩百分比显示出改善的功效。
■由于皮肤沉积增加和持续释放，莫匹罗星钙NLCs的乳液似乎可有效治疗受污染的伤口，从而增强现有分子的伤口愈合潜力。
